The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report

Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in...

Descripción completa

Detalles Bibliográficos
Autores principales: Badran, Ahmed, Steele, Clara, Alquaydheb, Hisham, Ba Theeb, Ahmed, Bawazir, Abdulmalik, Elshenawy, Mahmoud A., Atallah, Jean Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601707/
https://www.ncbi.nlm.nih.gov/pubmed/37900840
http://dx.doi.org/10.1159/000532099
_version_ 1785126247883341824
author Badran, Ahmed
Steele, Clara
Alquaydheb, Hisham
Ba Theeb, Ahmed
Bawazir, Abdulmalik
Elshenawy, Mahmoud A.
Atallah, Jean Paul
author_facet Badran, Ahmed
Steele, Clara
Alquaydheb, Hisham
Ba Theeb, Ahmed
Bawazir, Abdulmalik
Elshenawy, Mahmoud A.
Atallah, Jean Paul
author_sort Badran, Ahmed
collection PubMed
description Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.
format Online
Article
Text
id pubmed-10601707
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-106017072023-10-27 The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report Badran, Ahmed Steele, Clara Alquaydheb, Hisham Ba Theeb, Ahmed Bawazir, Abdulmalik Elshenawy, Mahmoud A. Atallah, Jean Paul Case Rep Oncol Case Report Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options. S. Karger AG 2023-08-28 /pmc/articles/PMC10601707/ /pubmed/37900840 http://dx.doi.org/10.1159/000532099 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Badran, Ahmed
Steele, Clara
Alquaydheb, Hisham
Ba Theeb, Ahmed
Bawazir, Abdulmalik
Elshenawy, Mahmoud A.
Atallah, Jean Paul
The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
title The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
title_full The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
title_fullStr The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
title_full_unstemmed The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
title_short The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
title_sort use of crizotinib in sclerosing epithelioid fibrosarcoma with alk mutation: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601707/
https://www.ncbi.nlm.nih.gov/pubmed/37900840
http://dx.doi.org/10.1159/000532099
work_keys_str_mv AT badranahmed theuseofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT steeleclara theuseofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT alquaydhebhisham theuseofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT batheebahmed theuseofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT bawazirabdulmalik theuseofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT elshenawymahmouda theuseofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT atallahjeanpaul theuseofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT badranahmed useofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT steeleclara useofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT alquaydhebhisham useofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT batheebahmed useofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT bawazirabdulmalik useofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT elshenawymahmouda useofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport
AT atallahjeanpaul useofcrizotinibinsclerosingepithelioidfibrosarcomawithalkmutationacasereport

Ejemplares similares